Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 366 | 371 | 528 | 598 | 659 |
| Marketable Securities | 493 | 607 | 612 | 616 | 601 |
| Receivables | 16 | 27 | 25 | 27 | 23 |
| Inventories | 8 | 12 | 6 | 10 | 15 |
| TOTAL | $883 | $1,016 | $1,171 | $1,250 | $1,298 |
| Non-Current Assets | |||||
| PPE Net | 313 | 316 | 330 | 345 | 342 |
| Investments And Advances | 12 | 12 | 12 | 12 | 12 |
| Other Non-Current Assets | 24 | 0 | 0 | 0 | 0 |
| TOTAL | $349 | $328 | $342 | $357 | $354 |
| Total Assets | $1,231 | $1,344 | $1,513 | $1,607 | $1,652 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 19 | 8 | 45 | 47 | 11 |
| TOTAL | $52 | $27 | $64 | $66 | $63 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 12 | 0 | 0 | 0 | 0 |
| TOTAL | $57 | $54 | $59 | $63 | $67 |
| Total Liabilities | $109 | $81 | $123 | $130 | $130 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 856 | 911 | 622 | 622 | N/A |
| Common Shares | 6,485 | 6,555 | 6,648 | 6,648 | 6,648 |
| Retained earnings | -333 | -241 | -219 | -148 | -87 |
| Other shareholders' equity | -17 | -38 | -27 | -10 | -27 |
| TOTAL | $1,122 | $1,264 | $1,390 | $1,478 | $1,522 |
| Total Liabilities And Equity | $1,231 | $1,344 | $1,513 | $1,607 | $1,652 |